Log In
BCIQ
Print this Print this
 

AAV10-FXN (ANN-003)

  Manage Alerts
Collapse Summary General Information
Company Adverum Biotechnologies Inc.
DescriptionAdeno-associated viral serotype 10 (AAV10) vector delivering the human frataxin (FXN; FRDA) gene
Molecular Target Frataxin (FXN) (FRDA)
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Adeno-associated virus (AAV)
Latest Stage of DevelopmentPreclinical
Standard IndicationAtaxia
Indication DetailsTreat Friedreich's ataxia (FRDA)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$105.6M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/12/2016

$105.6M

0

0

Get a free BioCentury trial today